HC Wainwright Comments on BioXcel Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:BTAI)

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of BioXcel Therapeutics in a research report issued to clients and investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.51) for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.61) EPS.

A number of other research firms have also recently commented on BTAI. Bank of America reduced their price target on BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, March 13th. UBS Group reiterated a “neutral” rating and set a $4.00 price target (down previously from $9.00) on shares of BioXcel Therapeutics in a report on Wednesday, February 21st. Finally, Canaccord Genuity Group reduced their price target on BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, March 14th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $16.86.

BioXcel Therapeutics Stock Performance

BioXcel Therapeutics stock opened at $2.55 on Wednesday. BioXcel Therapeutics has a 52 week low of $1.91 and a 52 week high of $29.56. The stock has a market capitalization of $77.98 million, a P/E ratio of -0.41 and a beta of 0.40. The stock has a 50-day simple moving average of $2.88 and a 200 day simple moving average of $3.17.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Tuesday, March 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.22. BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. The business had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.17 million.

Institutional Investors Weigh In On BioXcel Therapeutics

Several institutional investors have recently made changes to their positions in BTAI. Swiss National Bank boosted its stake in shares of BioXcel Therapeutics by 9.2% in the first quarter. Swiss National Bank now owns 46,300 shares of the company’s stock valued at $968,000 after buying an additional 3,900 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of BioXcel Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 13,606 shares of the company’s stock valued at $284,000 after buying an additional 1,870 shares during the period. Raymond James & Associates bought a new stake in shares of BioXcel Therapeutics in the first quarter valued at approximately $229,000. Bank of New York Mellon Corp boosted its stake in shares of BioXcel Therapeutics by 2.9% in the first quarter. Bank of New York Mellon Corp now owns 58,386 shares of the company’s stock valued at $1,220,000 after buying an additional 1,637 shares during the period. Finally, MetLife Investment Management LLC boosted its stake in shares of BioXcel Therapeutics by 57.0% in the first quarter. MetLife Investment Management LLC now owns 9,853 shares of the company’s stock valued at $206,000 after buying an additional 3,577 shares during the period. 30.68% of the stock is currently owned by institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.